| 000 | 01821 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515050929.0 | ||
| 264 | 0 | _c20080214 | |
| 008 | 200802s 0 0 chi d | ||
| 022 | _a0253-3766 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMeng, Qing-Wei | |
| 245 | 0 | 0 |
_a[Enhancement of HER-2 degradation by carbamazepine in breast cancer SKBR-3 cell line]. _h[electronic resource] |
| 260 |
_bZhonghua zhong liu za zhi [Chinese journal of oncology] _cJul 2006 |
||
| 300 |
_a503-6 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcetylation _xdrug effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aBenzoquinones _xpharmacology |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aBreast Neoplasms _xmetabolism |
| 650 | 0 | 4 |
_aCarbamazepine _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aDown-Regulation _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 |
_aHSP90 Heat-Shock Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHistone Deacetylase Inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLactams, Macrocyclic _xpharmacology |
| 650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xgenetics |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 | _aTrastuzumab |
| 700 | 1 | _aZhao, Chang-Hong | |
| 700 | 1 | _aXi, Yu-Hui | |
| 700 | 1 | _aCai, Li | |
| 700 | 1 | _aSun, Li-Chun | |
| 700 | 1 | _aSui, Guang-Jie | |
| 773 | 0 |
_tZhonghua zhong liu za zhi [Chinese journal of oncology] _gvol. 28 _gno. 7 _gp. 503-6 |
|
| 999 |
_c16716881 _d16716881 |
||